AMI Pharm Co Ltd
Corea del Sur
Sitio web: http://www.amipharm.com/en/
Número de stand: C106
Categorías industriales
- Medicinas - Productos farmaceuticos
- Cosmecéutica - Productos antiedad
- Lipofilling - Dispositivo y equipo de liposucción e injerto de grasa
Perfil de la empresa
Our leading pipeline, AYP-101, a Phase 3 clinical study for the improvement of submental fat has completed, with a planned lauch in 2026.
We found that the API of AYP-101 caused adipocyte-specific apoptosis and lipolysis, marking the first such finding in the world. With these goundbreaking findings, we started an audacious journey to develop the next generation of fat reduction treatments to meet the unmet needs in current cosmetic plastic surgery for fat reduction.
Through our efforts to develop a safe and stable injectable formulation of AYP-101 using its insolubale API, we successfully developed AYP-101 injection. We have also sucessfully completed non-clinical trials in accordance with ICH guidelines, as well as one Phase 1 clinical trial and two Phase 2 clinical trials.
We would like to take this great journey together with our partner.